Physician profile
Michael S Fitzpatrick
NPI 1043233695
$331.74
in general payments reported to CMS, 2019-2025
14 companies · $26.84 in 2025
The $26.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.49 · 2020: $37.32 · 2021: $20.04 · 2022: $58.90 · 2023: $77.13 · 2024: $48.02 · 2025: $26.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $51.18 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $36.47 | 2023-2024 | Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $27.29 | 2024 | Voquezna |
| Novo Nordisk INC | $26.29 | 2019-2022 | |
| Lilly USA, LLC | $26.06 | 2019-2022 | |
| Abbott Laboratories | $23.32 | 2023 | Freestyle Libre |
| Medtronic, INC. | $22.22 | 2023 | Intellis Adaptivestim |
| Abbvie INC. | $20.04 | 2021 | |
| Amarin Pharma, INC. | $19.83 | 2020 | |
| Paratek Pharmaceuticals, INC. | $18.75 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.49 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.85 | 2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $13.82 | 2022 | |
| Pfizer INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.